Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Prostate Cancer · Metastatic Castration-resistant Prostate Cancer · mCRPC · Urogenital Neoplasms · Prostatic Neoplasms · Prostatic Diseases

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Biogenix Molecular LLC, Miami, Florida, United States
Contact: Study coordinator (Jerry Joseph) · jjoseph@cira-health.com · 786-791-1799
Contact: Principal Investigator (Cesar Santana, MD)
NovaCure Health, Miami, Florida, United States
Contact: Study coordinator (Anibal Munguia Midence) · amunguia@novacurehealth.com · 786-485-0770
Contact: Principal Investigator (Serguei Castaneda, MD)
Emory University Hospital, Atlanta, Georgia, United States
Contact: Study coordinator (David Michael Schuster) · dschust@emory.edu · 404-778-5625
Contact: Study coordinator (Nashwa Jarkas) · njarkas@emory.edu · 404-727-2193
Contact: Principal Investigator (David Michael Schuster, MD)
XCancer Omaha / Urology Cancer Center, Omaha, Nebraska, United States
Nordquist · drnordquist@gucancer.com · (402) 991-8468
Contact: Principal Investigator (Luke Nordquist, MD)
Weill Cornell Medicine - New York - Presbyterian Hospital, New York, New York, United States
Saint Luc University Hospital, Brussels, Belgium
Contact: Study coordinator (Emmanuel Seront) · emmanuel.seront@saintluc.uclouvain.be · +32 (2764) 51 06
University Hospital Ghent, Ghent, Belgium
Contact: Study coordinator (Charles van Praet) · charles.vanpraet@uzgent.be · +32 (9) 332 1955
University Hospital Leuven, Leuven, Belgium
Contact: Study coordinator (Karolien Goffin) · karolien.goffin@uzleuven.be · +32 16 34 37 15
University Hospital Aachen, Aachen, Germany
Contact: Study coordinator (Felix Mottaghy) · fmottaghy@ukaachen.de · +49 241 80-35905
Universitätsklinikum Augsburg, Augsburg, Germany
Contact: Study coordinator (Constantin Lapa) · constantin.lapa@uk-augsburg.de · 0821 400 -168952
University Hospital Essen, Essen, Germany
Contact: Study coordinator (Boris Hadaschik) · boris.hadaschik@uk-essen.de
Hospital Rechts der Isar, Munich, Germany
Contact: Study coordinator (Matthias Eiber) · matthias.eiber@tum.de · +49 (89) 41404549
Radboud UMC, Nijmegen, Gelderland, Netherlands
Contact: Study coordinator (Nagarajah, MD) · james.nagarajah@radboudumc.nl
Meander Medisch Centrum, Amersfoort, Netherlands
Contact: Study coordinator (Joyce van Dodewaard-de Jong) · jm.van.dodewaard@meandermc.nl · 033-850 7278
Bristol Hematology and Oncology Center, Bristol, United Kingdom
Contact: Study coordinator (Amarnath Challapalli, MD) · Amarnath.Challapalli@uhbw.nhs.uk · +44 (0) 117 923 0000
Beatson West of Scotland Cancer Center, Glasgow, United Kingdom
Contact: Study coordinator (David Colville) · dave.colville@glasgow.ac.uk · +44 (0) 141 301 7000
St Bartholomew's Hospital, London, United Kingdom
Contact: Study coordinator (Kenrick Ng, MD) · kenrick.ng3@nhs.net · +44 (0)20 7377 700
James Cook University Hospital, Middlesbrough, United Kingdom
Contact: Study coordinator (Darren Leaning, MD) · d.leaning@nhs.net · +44 (0) 164285 0850
Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Contact: Study coordinator (Philip Camilleri) · philip.camilleri@ouh.nhs.uk · +44 (0)1865 572033
Weston Park, Sheffield, United Kingdom
Contact: Study coordinator (Omar Din) · o.din@nhs.net · +44 (0) 114226 5068
University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Contact: Study coordinator (Simon Crabb, MD) · s.j.crabb@southampton.ac.uk · +44 (0) 2381 205 170

Study leads

Blue Earth Therapeutics
Study Director
Blue Earth Therapeutics

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Phoenix, United States · Tucson, United States

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Metastatic Castration-Resistant Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Goodyear, United States · Scottsdale, United States

Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT

Prostate Cancer · Localized Prostate Carcinoma

Abroad (travel likely)RecruitingPHASE2

Miami, United States

Prospective Clinical Trial of 177Lu-P17-088 in the Treatment of Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Abroad (travel likely)RecruitingPHASE2

Fuzhou, China